EUVIMEDEUVIMED entdecken
Crossref

Clinical utility and prognostic value of GATA3 in epithelioid malignant mesothelioma: a practical and cost-effective approach for resource-limited settings

Dina Moustafa Thabit, Dalia M Thabet

Journal of Clinical Pathology · 2026-07 · 79 (7) · 475-485

DOI: 10.1136/jcp-2026-210673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Pathology, online erschienen am 14.05.2026. Verfasst von Dina Moustafa Thabit und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Faculty of Medicine, Minia University, Minia, Egypt dina.mostafa@mu.edu.eg. Hauptthemen laut MEDLINE: GATA3 Transcription Factor, Biomarkers, Tumor, Mesothelioma, Malignant, Lung Neoplasms. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Distinguishing epithelioid malignant mesothelioma (EMM) from poorly differentiated lung adenocarcinoma (PD-LUAD) remains challenging, particularly when 21.7% of PD-LUADs lack lineage-specific markers (thyroid transcription factor-1 (TTF-1)/Napsin A), creating a diagnostic blind spot. While GATA-binding protein 3 (GATA3) is established in sarcomatoid mesothelioma, its complementary diagnostic value and prognostic relevance in EMM are not well defined.

Methods

This retrospective study analysed 115 tissue specimens (55 EMMs; 60 PD-LUADs). Immunohistochemistry for GATA3, calretinin, Wilms’ tumour gene 1 (WT-1), TTF-1, Napsin A and pan-cytokeratin was performed. Results were correlated with clinicopathological parameters and overall survival (OS) using Kaplan–Meier and multivariate Cox regression analyses.

Results

GATA3 was expressed in 78.2% of EMM but only 6.7% of PD-LUAD cases (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GATA3 Transcription FactorBiomarkers, TumorMesothelioma, MalignantLung NeoplasmsMesotheliomaAdenocarcinoma of LungHumansFemaleRetrospective StudiesMaleAgedMiddle AgedImmunohistochemistryPrognosisDiagnosis, DifferentialAdultAged, 80 and overPredictive Value of TestsCost-Benefit Analysis

Stichwörter der Autor:innen

IMMUNOHISTOCHEMISTRYLung NeoplasmsPLEURA

Substanzen

GATA3 Transcription FactorGATA3 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Faculty of Medicine, Minia University, Minia, Egypt dina.mostafa@mu.edu.eg.
  • Department of Pathology, Faculty of Medicine, Minia University, Minia, Egypt.

Zitieren

APA

Thabit, D. M., & Thabet, D. M. (2026). Clinical utility and prognostic value of GATA3 in epithelioid malignant mesothelioma: a practical and cost-effective approach for resource-limited settings. Journal of Clinical Pathology, 79(7), 475-485. https://doi.org/10.1136/jcp-2026-210673

Vancouver

Thabit DM, Thabet DM. Clinical utility and prognostic value of GATA3 in epithelioid malignant mesothelioma: a practical and cost-effective approach for resource-limited settings. Journal of Clinical Pathology. 2026;79(7):475-485. doi:10.1136/jcp-2026-210673

BibTeX
@article{Thabit2026,
  author = {Thabit, Dina Moustafa and Thabet, Dalia M},
  title = {Clinical utility and prognostic value of GATA3 in epithelioid malignant mesothelioma: a practical and cost-effective approach for resource-limited settings},
  journal = {Journal of Clinical Pathology},
  year = {2026},
  volume = {79},
  number = {7},
  pages = {475--485},
  doi = {10.1136/jcp-2026-210673}
}
Kostenlos starten →